Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90002 in R/R AML and High-Risk MDS
NCT02641002Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CC-90002 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Primary endpoints: Dose-limiting Toxicity up to 26 months, Non-tolerated Dose up to 26 months and 1 more. Started Mar 2016; status: terminated.
02
Drugs
CC-90002
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02641002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641002.